With the U.S. FDA giving the green light to Takeda Pharmaceutical Co. Ltd.’s Adzynma for treating a rare blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme, the company has won two approvals in two days after the FDA approved fruquintinib a day earlier. Read More
With Valneva SE’s accelerated approval from the U.S. FDA for chikungunya vaccine Ixchiq, attention turned to the February 2024 meeting of the Advisory Committee on Immunization Practices (ACIP), which will vote on the product. A single-dose, live-attenuated vaccine, Ixchiq is designed to prevent disease caused by the virus in people 18 and older who are at increased risk of exposure to the bug. Read More
Astrazeneca plc will pay up to $2 billion for Eccogene Co. Ltd.’s oral weight loss candidate, ECC-5004, as big and small pharma players alike work to gain ground in the burgeoning obesity market where Eli Lilly and Co. scored the latest U.S. FDA approval of Zepbound (tirzepatide). Read More
The artificial intelligence company Recursion Pharmaceuticals Inc. and Bayer AG have upped the ante on their 2020 collaboration deal to include precision oncology, with the possibility of more than $1 billion in potential milestone payments for Recursion. Read More
In one of the larger biopharma IPOs in 2023, Cargo Therapeutics Inc. pulled in $281.3 million on Nov. 10, selling 18.75 million shares at $15 each, the low end of its price range. The market debut comes just eight months after the San Mateo, Calif.-based company raised $200 million in an oversubscribed series A round. Read More
October marked a historic milestone for the biopharma industry, with deal values hitting $44.91 billion. It was the highest amount ever recorded by BioWorld, topping a deal value of $42.45 billion in December 2022. While the cumulative value of biopharma deals through Q3 lagged behind the previous year, October’s outstanding value has catapulted this year ahead. In the first 10 months of 2023, deal value reached $175.2 billion, compared to $148.56 billion recorded in the same period in 2022. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astrazeneca, Atara, Ikena, Immutep, Janssen, Kiromic, Oncolytics, PDS, Pharmabcine, Recce, Senhwa, SFA, Trishula, Vaxcyte. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adaptive, Biocryst, Kallyope, Sosei. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Artax, Daiichi, Takeda. Read More
